SpotitEarly
SpotitEarly55About
What does SpotitEarly do?
SpotitEarly offers a single at-home breath test for pre-screening multiple cancer types, including breast, colorectal, lung, and prostate. This non-invasive, accessible test leverages the science of Volatile Organic Compounds (VOCs) in exhaled breath to detect early-stage cancer. The company aims to increase cancer screening adoption by providing an affordable and convenient solution for individuals.
What is SpotitEarly's revenue?
StartupHub estimates SpotitEarly's annual revenue at $3.8M (range $2.8M to $7.6M, 64% confidence), based on comparable companies in the sector.
What is SpotitEarly's valuation?
StartupHub estimates SpotitEarly's effective valuation at $24.9M (range $15.5M to $37.2M, 10% confidence), based on comparable companies in the sector.
How much funding has SpotitEarly raised?
SpotitEarly has raised a total of $6M in funding. The most recent round on record is Seed.
Where is SpotitEarly headquartered?
SpotitEarly is headquartered in Tel Aviv, Israel.
When was SpotitEarly founded?
SpotitEarly was founded in 2021.
What industry does SpotitEarly operate in?
SpotitEarly operates in Healthcare, HealthTech, MedTech, Biotech, Drug Discovery, AI-Driven Drug Discovery.
How many employees does SpotitEarly have?
SpotitEarly has approximately 17 people on record.
No comments yet. Be the first to share your take.